First quarter 2024 results
First quarter 2024 results were reviewed by management during a conference call with the financial community on April 25th. The presentation was followed by a Q&A session.
14:30 - 16:00 CET (8:30am – 10am EST)
Upcoming events
15May
2024
BofA Securities Health Care Conference 2024
Speakers: Manuela Buxo - Global Head of Dupixent Franchise & Elizabeth Laws - Global Program Head, Dupixent
12:00
Broker Conference
21May
2024
21May
2024
Press releases
May 13, 2024
Press Release: Sanofi adds over €1 billion for biomanufacturing to €2.5 billion already committed in major projects in France to support health sovereignty
May 10, 2024
Press Release: Sanofi and Novavax announce co-exclusive licensing agreement to co-commercialize COVID-19 vaccine and develop novel flu-COVID-19 combination vaccines
May 2, 2024
Press Release: Beyfortus real-world evidence published in The Lancet shows 82% reduction in infant RSV hospitalizations
Environment, Social, Governance
As a global pharmaceutical company, we stretch everyday to deliver safe and sustainable innovation and play our part in addressing some of the world’s most pressing challenges.
Contact Our Investor Relations Team
To join the Sanofi front desk,
Please contact the Global Headquarters in France :
+33 (0)1 53 77 40 00
To contact the Investor Relations team:
46 avenue de la Grande Armée
75017 Paris FRANCE
investor.relations (at) sanofi.com